Tuesday, October 2, 2018
Seattle Genetics price target raised to $98 from $90 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Seattle Genetics to $98 and kept his Outperform rating, saying its ECHELON-2 trial “exceeded best case scenario” with a “surprise” overall survival benefit. The analyst notes that the results were a “clean win with E-2’s magnitude of PFS benefit”, raising his probability of success for the program to 100% from 75%.
https://thefly.com/landingPageNews.php?id=2798375
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.